Report Description of the EU Parkinson’s Disease Treatment Market Analysis
Research Scope and Assumption
- The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
- The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
- We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
- All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
- Inflation has not been accounted for in order to estimate and forecast the market
- Numbers may not add up due to rounding off
Reason to buy the report:
- Facilitate decision-making based on strong current and forecast data for EU Parkinson’s Disease Treatment Market Analysis
- Develop strategies based on the latest regulatory framework
- Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
- Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU Parkinson’s Disease Treatment Market Analysis
- Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
- To strategically profile key players and comprehensively analyze their market shares and core competencies
- We have technically sound team which do a deep dive research and also provide strategy based consulting analysis
EU Parkinson’s Disease Treatment Market Analysis Executive Summary
Parkinson’s disease is termed as a progressive neurodegenerative disorder that affects dopaminergic neurons in the brain. Parkinson’s disease mainly causes tremors, muscle stiffness, abnormal movement, walking, and balance problems. Secondary symptoms of this ailment include anxiety, depression, and dementia. The exact etiology of Parkinson’s disease is unknown and mainly affects older people over the age of 50, but men suffer half of the women’s illnesses. According to estimates by the United States Parkinson Foundation, the disease affects about 70 to 10 million people worldwide, and about 50,000 Americans are diagnosed with the disease each year. In developed regions like Europe, the high prevalence and risk of this disease are driving the growth of the Parkinson’s disease treatment market.
Market Size and Key Findings
The EU Parkinson’s Disease Treatment Market Analysis size stood at around USD 1.4 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 5.88% during the forecast period.
The size of the Europe Parkinson’s Disease Treatment Market was worth USD 1.4 billion in 2020 and estimated to be growing at a CAGR of 5.88% by 2028.
Market Growth Drivers Analysis
Parkinson’s Disease Treatment market propels with a growing public understanding of this disease, the multiplying elderly population, the prospect of launching pipeline drugs and new products, and relatively high growth in the therapeutic market. The government and non-profit organizations understanding of Parkinson’s disease and higher clinical research and development budgets are expected to drive the growth of the Parkinson’s treatment market over the forecast period. Promising product channels represent potential business development opportunities over the projection period.
It is expected that the patent expiry of crucial drugs and side effects related to therapeutic medicines will limit the growth of Europe’s Parkinson’s disease treatment market over the forecast period.
COVID-19 impact on “EU Parkinson’s Disease Treatment Market”
People with Parkinson’s disease face a higher risk of dying from Covid-19 – and studies have also indicated that the conditions created by the pandemic have impacted sleep disturbances and medication access for many of those living the condition. The immediate negative consequences of the COVID-19-period for People with Parkinson’s disease (PwP) may not be as severe as expected. Conversely, patient ratings and free-text descriptions suggest that, despite increased anxiety, the pandemic and related changes in society are associated with improvement in Health-Related Quality of Life (HRQL), better night sleep and an overall feeling that the “pressure” is gone.
Leading companies dominating the European Parkinson’s Disease Treatment Market profiled in this report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US). Boehringer Ingelherm (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
Products in Pipeline
According to the Parkinson’s Disease Clinic and Research Center, University of California, US, gene therapy for Parkinson’s disease has shown promising results in phase I studies. Phase II and III studies are currently under progress. Surgical treatments, restriction on the use of medications in severe stages of the disease, and the increased focus on gene therapy research are expected to restrain the demand for therapeutic drugs used in Parkinson’s disease.
Notable Recent Deals
- In 2016, ACADIA Pharmaceuticals, Inc. (U.S.) received FDA approval for its NUPLAZID drug.
- In 2016, Sun Pharmaceutical Industries Ltd. (India) entered distribution agreement with Mitsubishi Tanabe Pharma Corporation (Japan) to distribute 14 prescription brands that include Parkinson’s disease drug Parlodel in Japan.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
The European Parkinson’s Disease Association (EPDA) is the only European Parkinson’s Umbrella Organization. We have been championing and working with the global Parkinson’s community for nearly 30 years. Since the EPDA was founded, back in 1992, their focus has always been 100% on collaboration and building unity across Europe and the world. While national Organizations work on national agendas in their own countries, we strive to unite the international Parkinson’s community to work together to achieve common goals and to pursue the EPDA vision: to enable all people with Parkinson’s to live a full life, while supporting the search for a cure.